Dr. John Goudreau received his medical degree and doctorate in neuropharmacology through the DO-PhD program at Michigan State University College of Osteopathic Medicine (MSUCOM) in 1995. He completed his residency in neurology at the Mayo Clinic in 2000, where he was given the Mayo Brothers Distinguished Fellowship Award. After residency, Dr. Goudreau completed a movement disorders fellowship at the Mayo Clinic, with a special interest in the genetics of movement disorders and advanced clinical training in the neurophysiology and botulinum toxin treatment of abnormal movements.

Dr. Goudreau joined the MSUCOM faculty in July 2001, where he continues his scientific and clinical interests in Parkinson’s disease and other movement disorders as a tenured associate professor in the Departments of Neurology and Pharmacology-Toxicology.  In 2019, he was selected as the Associate Dean for Research in the MSU College of Osteopathic Medicine and co-director of the DO-PhD training program, a combined degree program where students are trained to become physician scientists.  He was also appointed at the Director of the MSU Clinical & Translational Science Institute, which facilitates university-wide clinical/translational research infrastructure.

 Dr. Goudreau’s research is focused on developing symptomatic and neuroprotective therapies for Parkinson’s and related neurodegenerative disorders. Dr. Goudreau is board certified in neurology and was elected a fellow of the American Osteopathic Board of Neurology and Psychiatry. He is an active member of the American Academy of Neurology, Movement Disorders Society, Parkinson Study Group and the American Osteopathic Association. Dr. Goudreau was elected as a member of the NBOME Board during its December 2014 Annual Meeting, has formerly served in COMLEX-USA Level 2-CE and Level 1 Coordinator roles, and as chair of the Clinical Decision-making Subcommittee. He is also a member of the COMLEX-USA Level 3 Advisory Committee.


Academic Appointments

2006-Present: Associate Professor, Neurology & Pharmacology/Toxicology, Michigan State University, 2006-Present: Director, Movement Disorders Sub-Specialty Clinic, Neurology, Michigan State University, 2005-Present: Director, Translational Neurobiology Unit, Neurology, Michigan State University, 2001-2006: Assistant Professor, Neurology & Pharmacology/Toxicology, Michigan State University


  • Ph.D., Neuropharmacology, Michigan State University; East Lansing, MI 1994
  • D.O., Michigan State University College of Osteopathic Medicine; East Lansing, MI 1995
  • B.S., Medical Technology, Lyman Briggs School, Michigan State University; East Lansing, MI 1988
  • B.A., Chemistry, Michigan State University; East Lansing, MI 1988

Postdoctoral Training

Movement Disorders Fellowship, Mayo Clinic; Rochester, MN 2001, Neurology Residency, Mayo Clinic; Rochester, MN 2000, Transitional Year, Mayo Clinic; Scottsdale, AZ 1997, Internship, Botsford General Hospital; Farmington Hills, MI 1996


  • Goudreau, JL, Burau K, Perez A, Aminoff, M, Bodis-Wollner, I, Fang, J, Tilley B for the NET-PD Investigators. Initial choice of dopaminergic therapy in the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Longitudinal Study-1 (LS-1). Arch Neurol, submitted, 2013.
  • Benskey, MJ, Lee, KY, Parikh K, Lookingland, KJ, Goudreau, JL. Resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein. Neurotoxiology, in press, 2013.
  • Tiernan CT, Edwin EA, Goudreau JL, Atchison WD, Lookingland KJ. The Role of De Novo Catecholamine Synthesis in Mediating Methylmercury-Induced Vesicular Dopamine Release from Rat Pheochromocytoma (PC12) Cells. Toxicol Sci. 2013 Mar 15. [Epub ahead of print] PubMed PMID: 23425605.
  • Hsu SC, Sears RL, Lemos RR, Quintáns B, Huang A, Spiteri E, Nevarez L, Mamah C, Zatz M, Pierce KD, Fullerton JM, Adair JC, Berner JE, Bower M, Brodaty H, Carmona O, Dobricić V, Fogel BL, García-Estevez D, Goldman J, Goudreau JL, Hopfer S, Janković M, Jaumà S, Jen JC, Kirdlarp S, Klepper J, Kostić V, Lang AE, Linglart A, Maisenbacher MK, Manyam BV, Mazzoni P, Miedzybrodzka Z, Mitarnun W, Mitchell PB, Mueller J, Novaković I, Paucar M, Paulson H, Simpson SA, Svenningsson P, Tuite P, Vitek J, Wetchaphanphesat S, Williams C, Yang M, Schofield PR, de Oliveira JR, Sobrido MJ, Geschwind DH, Coppola G. Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics. 14(1):11-22, 2013. PubMed PMID: 23334463.
  • Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 27(12):1513-21, 2012. PubMed Central PMCID: PMC3481179. PMID: 23079770
  • Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature; 490(7419):187-91, 2012.
  • Simkins TJ, Janis KL, McClure AK, Behrouz B, Pappas SJ, Lehner A, Kaminski N, Goudreau JL, Lookingland KJ, Kaplan BL. Comparison of the D2 receptor regulation of neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice. J Neuroimm Pharm, 7(3):533-538, 2012.
  • Benskey M, Behrouz B, Sunryd J, Pappas SS, Baek SH, Huebner M, Lookingland KJ, Goudreau JL. Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression. Neurotoxicology. 33(3):321-331, 2012.
  • Lee KY, Bae ON, Serfozo K, Hejabian S, Moussa A, Reeves M, Rumbeiha W, Fitzgerald SD, Stein G, Baek SH, Goudreau J, Kassab M, Majid A. Asiatic Acid Attenuates Infarct Volume, Mitochondrial Dysfunction, and Matrix Metalloproteinase-9 Induction After Focal Cerebral Ischemia. Stroke. 43(6):1632-8, 2012. PMCID: PMC3361557 PMID: 22511009.
  • Ravizza SM, Goudreau J, Delgado MR, Ruiz S. Executive function in Parkinson's disease: contributions of the dorsal frontostriatal pathways to action and motivation. Cogn Affect Behav Neurosci. 12(1):321-331, 2011 PMID: 22006555.
  • Pappas, S., Kennedy, T., Goudreau, J.L., Lookingland, K.J., Opioid-mediated regulation of A11 diencephalospinal dopamine neurons: pharmacological evidence of activation by morphine, Neurpharmacology, 2011, Neuropharmacology;61(4):614-21, 2011.
  • Parkinson Study Group PramiBID Investigators, Twice daily, low-dose pramipexole in early Parkinon’s disease: A randomized, placebo-controlled trial, Movement Disorders, 26:37-55, 2011.
  • Lerner, A., Johnson, Simkins T.J., Janis K.L., Lookingland, K.J., Goudreau, J.L., Rumbieha, W. Liquid Chromatographic—Electrospray Mass Spectrometric Determination of 1-Methyl-4-phenylpyridine (MPP+) in Discrete Regions of Murine Brain. Toxicology Mech Methods, 21:171-182, 2011.
  • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24;361(13):1268-78.
  • Han D, Yang B, Olson LK, Greenstein A, Baek SH, Claycombe KJ, Goudreau JL, Yu SW, Kim EK; Activation of autophagy through modulation of amp-activated protein kinase protects pancreatic beta-cells from hyperglycemia, Biochemical J., 425:541:-551, 2010.
  • Pappas SS, Tiernan, CT, Behrouz, B, Jordan C, Breedlove SM, Goudreau, JL, Lookingland KJ. Neonatal androgen-dependent sex differences in lumbar spinal cord dopamine concentrations and the number of A11 diencephalospinal dopamine neurons. J Comp Neurol, 518:2423-2436, 2010.
  • Baek SH, Kim EK, Goudreau JL, Lookingland KJ, Kim SW, Yu SW. Insulin withdrawal-induced cell death in adult hippocampal neural stem cells as a model of autophagic cell death. Autophagy, 5:277-9, 2009
  • Krishnamurthy RG, Senut MC, Zemke D, Min J, Frenkel MB, Greenberg EJ, Yu SW, Ahn N, Goudreau J, Kassab M, Panickar KS, Majid A. Asiatic acid, a pentacyclic triterpene from Centella asiatica, is neuroprotective in a mouse model of focal cerebral ischemia. J Neurosci Res, 87(11):2541-50, 2009.


  • Tiernan CT, Edwin EA, Goudreau JL, Atchison WD, Lookingland KJ. Acute methylmercury exposure increases release of newly synthesized dopamine from PC12 cells via a vesicular-dependent mechanism. Soc Neurosci Abstr #66.23, October 13, 2012.
  • Benskey MJ, Lee K, Lookingland KJ, Goudreau JL. Differential susceptibility of central dopamine neurons to toxicant exposure is associated with changes in components of the ubiquitin proteasome pathway Soc Neurosci Abstr 440.14, October 13, 2012.
  • Simkins TJ, Crawford RB, Goudreau JL, Lookingland KJ, Kaplan, BLF. Cannabinoid-induced suppression of B cell antibody production is associated with a decrease of sympathetic noradrenergic neuronal activity in the spleen. Soc Neurosci Abstr 685.03, October 16, 2012.
  • Hawong H-Y, Goudreau JL, Lookingland, KJ, Comparison of synaptosomal mitochondrial function and integrity in brain regions containing axon terminals of nigrostriatal and tuberoinfundibular dopamine neurons in parkin-deficient mice, Michigan Society for Neuroscience, June, 2012.
  • Hawong H-Y, Lookingland, KJ, Goudreau JL. Bioenergetics analyses of synaptosomal mitochondria in parkin-deficient mice – evidence for a role of parkin in maintenance of mitochondrial quality. American Society for Biochemistry and Molecular Biology, June, 2012.
  • Hawong H-Y, Lookingland, KJ, Goudreau, JL. Impaired synaptosomal mitochondrial bioenergetics and mass in brain regions containing unique dopamine neuronal populations in parkin deficient mice, 26th Annual National MD/PhD Student Conference, Keystone, CO, July 2012.
  • Shen, L., Li, F., Goudreau, J.L., Rechtein, J., Snider, K., Wattleworth, R. Performance variation of osteopathic students at different educational levels in two essential areas. AAEE. 15th Ottowa Conference on International Medical Education, Kuala Lumpur, Malaysia, March 2012.
  • Shen, L., Li, F., Goudreau, J.L., Rechtein, J., Snider, K., Wattleworth, R. Retention of medical knowledge by osteopathic medical students, AACOM 2012.
  • Tiernan, C.T., M.A. Bernard-Flores, J.L. Goudreau, K.J. Lookingland, W.D. Atchison, 2011, Lack of effect of acute methylmercury exposure on tyrosine hydroxylase activity in nigrostriatal dopamine neurons in mice, Soc for Toxicol. Abstr. 1400-246.
  • Benskey, M., K.J. Lookingland, J.L. Goudreau, 2011, Recovery of Hypothalamic Dopamine Neurons to Acute Neurotoxic Insult is Prolactin Independent and Correlated with an Increase in Parkin Protein Expression, 23rd Biennial Meeting International & European Soc. Neurochemistry (INS-ENS), Athens Greece, August 28, 2011, TU05-01.
  • Tiernan, C., E. Edwin, J.L. Goudreau, W.D. Atchison, K.J. Lookingland, 2011, Methylmercury alters synthesis, release, and metabolism of dopamine in PC12 cells, 23rd Biennial Meeting International & European Soc. Neurochemistry (INS-ENS), Athens Greece, August 28, 2011.

Book Chapters

  • Goudreau, J.L., Ahlskog, J.E., Symptomatic Treatment of Parkinson’s Disease: Chapter 64, Levodopa, in Parkinson’s Disease, 2nd Edition. Ebadi, M and Pfeiffer, R. eds., CRC Press, New York, 2012.
  • Goudreau, J.L., Medical management of advanced Parkinson’s disease, Clinics in Geriatric Medicine, 22:753-772, 2006.
  • Goudreau, J.L. Hereditary Spinocerebellar Degeneration, in Neurological Therapeutics: Principles and Practice, 2nd Edition, John Noseworthy, ed. Martin Dunitz, London, In press, Chapter 214, 2006.
  • Goudreau, J.L., Ahlskog, J.E., Symptomatic Treatment of Parkinson’s Disease: Levodopa, in Parkinson’s Disease, Ebadi, M and Pfeiffer, R. eds., CRC Press, New York, Chapter 56, 713-728, 2005
  • Goudreau, J.L. Hereditary Spinocerebellar Degeneration, in Neurological Therapeutics: Principles and Practice, 1st Edition, John Noseworthy, ed. Martin Dunitz, London, Chapter 209, 2205-2213, 2003.

Research Interests

Neuroprotective treatments in Parkinson’s disease (PD) are needed to slow or halt the progressive deterioration of motor function that is associated with the relentless degeneration of nigrostriatal dopamine (DA) neurons. Advances in our understanding of the etiology and pathogenesis of PD have permitted the rational identification, pre-clinical testing, and selection of target compounds for testing in clinical trials. The overall goal of my research program at Michigan State University is to develop effective neuroprotective therapies for patients living with PD. To this end, I am pursuing a vertically integrated and translational approach that incorporates A) cutting-edge basic neuroscience research to identify novel neuroprotective targets, B) in vivo efficacy and safety screening of candidate neuroprotective compounds and C) clinical trials focused on neuroprotective therapies for patients with PD.

The current research environment provides a golden opportunity to move beyond symptomatic treatment with DA replacement medications and towards therapy that has a truly enduring benefit for patients living with PD. Truly translational research requires the careful alignment of basic science investigation, pre-clinical testing and clinical trials to achieve the ultimate goal of effective neuroprotective treatments in PD.

Please feel free to contact me if you have any questions about my research.

Current Research Support

  • 1 U10 NS053380-01 (NINDS) - Michigan State University Parkinson Disease Clinical Center
  • R01 NS065338-01A2 (NINDS) - The role of parkin in selective dopamine neuronal degeneration
  • INO-PD-P2-2008 Michael J. Fox Foundation - Safety of Urate Elevation in Parkinson’s Disease (SURE-PD)
  • TVP 1012-501  Teva Pharmaceuticals  - Adagio Follow-up Study
  • 1F31NS064783-01 Predoctoral NRSA for S. Pappas - All Diencephalospinal Dopamine Neurons and Restless Legs Syndrome
  • 60025165 Michael J. Fox Foundation  - Safety, Tolerability and Efficacy Analysis of DYnacirc CR in Parkinson Disease (STEADY-PD)


Distinguished Alumni Award, College of Osteopathic Medicine, Michigan State University; East Lansing, MI (2007), Best Doctors in America, Consumer’s Research Council of America (2005-2012), Mayo Brothers Distinguished Fellowship Award (2001), ASPET Student Research Travel Award (1993), L. D. Sills Research Award, College of Osteopathic Medicine, Michigan State University; East Lansing, MI (1992, 1994), Academic Excellence Award, Lyman Briggs, Michigan State University; East Lansing, MI (1988)


Board Certified, Neurology, American College of Osteopathic Neurology and Psychiatry, Board Certified, Neurology, American Board of Medical Specialties, American Board of Neurology and Psychiatry


Parkinson Study Group, American Society for Pharmacology and Experimental Therapeutics, Federation of American Societies for Experimental Biology, Society for Neuroscience, American Academy of Neurology, Movement Disorder Society, Fellow, American College of Neuropsychiatry , American Osteopathic Association, Michigan Osteopathic Association

Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

MSU is an affirmative action, equal opportunity employer

© Michigan State University Board of Trustees, East Lansing, MI 48824